アクセス数 : ?
ダウンロード数 : ?
ID 115614
タイトル別表記
NAFLD with elevation of alanine aminotransferase levels at various stages of metabolic syndrome
著者
曽我部, 正弘 Tokushima University|Shikoku Central Hospital of the Mutual aid Association of Public School Teachers 徳島大学 教育研究者総覧 KAKEN研究者をさがす
岡久, 稔也 Tokushima University|Shikoku Central Hospital of the Mutual aid Association of Public School Teachers 徳島大学 教育研究者総覧 KAKEN研究者をさがす
Kurihara, Takeshi Shikoku Central Hospital of the Mutual aid Association of Public School Teachers
Kagemoto, Kaizo Tokushima University
岡崎, 潤 Tokushima University
喜田, 慶史 Tokushima University
Hirao, Akihiro Tokushima University
田中, 宏典 Tokushima University
Nakasono, Masahiko Tsurugi Municipal Handa Hospital
資料タイプ
学術雑誌論文
抄録
Background
The prevalence of nonalcoholic fatty liver disease (NAFLD) in the non-obese population has increased and NAFLD is not always recognized in individuals with metabolic syndrome (MS). The risk of cirrhosis is higher in patients having NAFLD with elevated alanine aminotransferase (ALT) levels than in those having NAFLD with normal ALT levels.
Objective
To measure the differences in clinical factors associated with NAFLD having elevation of ALT among subjects with Non-MS, Pre-MS, and MS, and to measure differences in metabolites between MS subjects with and without NAFLD having elevation of ALT.
Methods
Among 7,054 persons undergoing health check-ups, we included 3,025 subjects who met the selection criteria. We measured differences in clinical factors for NAFLD having elevation of ALT among subjects with Non-MS, Pre-MS, and MS, and compared metabolites between subjects with and without NAFLD having elevation of ALT in 32 subjects with MS.
Results
The prevalence of NAFLD and NAFLD having elevation of ALT was significantly progressively greater in subjects with Non-MS, Pre-MS, and MS (p <0.001, respectively). In the Non-MS group, there were significant differences between subjects with and without NAFLD having elevation of ALT with respect to body mass index (BMI), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol, hemoglobin A1c, uric acid, aspartate aminotransferase (AST); In the Pre-MS group, there were significant differences in BMI, hypertension, AST, and gamma-glutamyl transpeptidase (GGT); In the MS group, there were significant differences in HDL-C, impaired glucose tolerance, AST, and GGT. There were significant differences in levels of metabolites of nicotinamide, inosine, and acetyl- L-carnitine between MS subjects with and without NAFLD having elevation of ALT (all p <0.05).
Conclusions
Although NAFLD having elevation of ALT is important for development of NAFLD, differences in factors associated with NAFLD having elevation of ALT at various stages of MS should be considered. Additionally, several metabolites may play roles in the identification of risk for NAFLD in individuals with MS.
掲載誌名
PLOS ONE
ISSN
19326203
出版者
PLOS
15
8
開始ページ
e0238388
発行日
2020-08-31
権利情報
© 2020 Sogabe et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
EDB ID
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
医学系
病院